Trends in Influenza Vaccination Rates among a Medicaid Population from 2016 to 2021
Author:
Naderalvojoud Behzad12ORCID, Shah Nilpa D.12, Mutanga Jane N.3, Belov Artur3, Staiger Rebecca1, Chen Jonathan H.1245, Whitaker Barbee3, Hernandez-Boussard Tina167ORCID
Affiliation:
1. Department of Medicine, Stanford University, Stanford, CA 94305, USA 2. Stanford Center for Biomedical Informatics Research, Stanford, CA 94305, USA 3. Center for Biologics Evaluation and Research, Office of Biostatistics and Pharmacovigilance, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA 4. Division of Hospital Medicine, Stanford, CA 94305, USA 5. Clinical Excellence Research Center, Stanford, CA 94304, USA 6. Department of Surgery, Stanford University School of Medicine, Stanford, CA 94305, USA 7. Department of Biomedical Data Science, Stanford University, Stanford, CA 94305, USA
Abstract
Seasonal influenza is a leading cause of death in the U.S., causing significant morbidity, mortality, and economic burden. Despite the proven efficacy of vaccinations, rates remain notably low, especially among Medicaid enrollees. Leveraging Medicaid claims data, this study characterizes influenza vaccination rates among Medicaid enrollees and aims to elucidate factors influencing vaccine uptake, providing insights that might also be applicable to other vaccine-preventable diseases, including COVID-19. This study used Medicaid claims data from nine U.S. states (2016–2021], encompassing three types of claims: fee-for-service, major Medicaid managed care plan, and combined. We included Medicaid enrollees who had an in-person healthcare encounter during an influenza season in this period, excluding those under 6 months of age, over 65 years, or having telehealth-only encounters. Vaccination was the primary outcome, with secondary outcomes involving in-person healthcare encounters. Chi-square tests, multivariable logistic regression, and Fisher’s exact test were utilized for statistical analysis. A total of 20,868,910 enrollees with at least one healthcare encounter in at least one influenza season were included in the study population between 2016 and 2021. Overall, 15% (N = 3,050,471) of enrollees received an influenza vaccine between 2016 and 2021. During peri-COVID periods, there was an increase in vaccination rates among enrollees compared to pre-COVID periods, from 14% to 16%. Children had the highest influenza vaccination rates among all age groups at 29%, whereas only 17% were of 5–17 years, and 10% were of the 18–64 years were vaccinated. We observed differences in the likelihood of receiving the influenza vaccine among enrollees based on their health conditions and medical encounters. In a study of Medicaid enrollees across nine states, 15% received an influenza vaccine from July 2016 to June 2021. Vaccination rates rose annually, peaking during peri-COVID seasons. The highest uptake was among children (6 months–4 years), and the lowest was in adults (18–64 years). Female gender, urban residency, and Medicaid-managed care affiliation positively influenced uptake. However, mental health and substance abuse disorders decreased the likelihood. This study, reliant on Medicaid claims data, underscores the need for outreach services.
Funder
Center of Excellence in Regulatory Science and Innovation HMS Australian Government’s Cooperative Research Centres Program
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference52 articles.
1. Provisional Mortality Data—United States, 2021;Ahmad;MMWR Morb. Mortal. Wkly. Rep.,2022 2. Deaths: Final Data 2019;Xu;Natl. Vital Stat. Rep.,2021 3. Seasonal Incidence of Symptomatic Influenza in the United States;Tokars;Clin. Infect. Dis.,2018 4. Centers for Disease Control and Prevention (2020, October 01). Past Seasons Estimated Influenza Disease Burden, Available online: https://www.cdc.gov/flu/about/burden/past-seasons.html. 5. Economic burden of seasonal influenza in the United States;Putri;Vaccine,2018
|
|